Arvinas Inc (NASDAQ:ARVN) Insider Ian Taylor Sells 10,000 Shares

Arvinas Inc (NASDAQ:ARVN) insider Ian Taylor sold 10,000 shares of Arvinas stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $28.00, for a total value of $280,000.00. Following the transaction, the insider now owns 55,496 shares in the company, valued at $1,553,888. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Ian Taylor also recently made the following trade(s):

  • On Monday, September 30th, Ian Taylor sold 10,000 shares of Arvinas stock. The shares were sold at an average price of $21.86, for a total value of $218,600.00.

Shares of Arvinas stock traded up $0.44 during trading hours on Friday, hitting $30.48. The company’s stock had a trading volume of 19,935 shares, compared to its average volume of 461,528. The business has a 50 day moving average price of $20.60 and a two-hundred day moving average price of $22.61. Arvinas Inc has a 12-month low of $10.19 and a 12-month high of $30.54. The company has a market cap of $896.04 million, a PE ratio of -1.20 and a beta of 2.13. The company has a debt-to-equity ratio of 0.03, a quick ratio of 6.79 and a current ratio of 6.79.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.21 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.67. The business had revenue of $30.05 million for the quarter, compared to the consensus estimate of $11.42 million. Arvinas had a negative return on equity of 31.57% and a negative net margin of 157.34%. As a group, research analysts anticipate that Arvinas Inc will post -2.13 earnings per share for the current year.

Several equities analysts have recently commented on ARVN shares. Zacks Investment Research downgraded Arvinas from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 7th. BMO Capital Markets started coverage on Arvinas in a research report on Thursday, September 12th. They issued an “outperform” rating and a $34.00 price objective on the stock. Goldman Sachs Group upgraded Arvinas from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $23.00 to $38.00 in a research report on Thursday, October 24th. Cantor Fitzgerald started coverage on Arvinas in a research report on Monday, August 5th. They issued an “overweight” rating and a $42.00 price objective on the stock. Finally, Roth Capital started coverage on Arvinas in a research report on Thursday. They issued a “buy” rating and a $35.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Arvinas has a consensus rating of “Buy” and an average price target of $32.75.

Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its position in shares of Arvinas by 21.8% in the second quarter. JPMorgan Chase & Co. now owns 13,358 shares of the company’s stock worth $317,000 after buying an additional 2,387 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Arvinas by 14,782.2% in the second quarter. Bank of America Corp DE now owns 232,609 shares of the company’s stock worth $5,116,000 after buying an additional 231,046 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Arvinas by 137.7% in the second quarter. Bank of New York Mellon Corp now owns 56,505 shares of the company’s stock worth $1,243,000 after buying an additional 32,733 shares in the last quarter. Swiss National Bank purchased a new stake in shares of Arvinas in the second quarter worth about $462,000. Finally, BlackRock Inc. lifted its position in shares of Arvinas by 124.5% in the second quarter. BlackRock Inc. now owns 1,038,838 shares of the company’s stock worth $22,845,000 after buying an additional 576,137 shares in the last quarter. Institutional investors own 46.79% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer.

Featured Article: Market Indexes

Insider Buying and Selling by Quarter for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.